Skip to content

Atellica IM CA 125II 10995481Recalls & reported problems

Siemens Healthcare Diagnostics Inc. · CA 125II Atellica IM - RGT 100T · Class 2

Data updated Oct 18, 2026 from official FDA records · Editorial policy

Adverse event reports
2
Deaths reported
0
Injuries reported
0
Recalls naming it
0

Summary

The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 00630414598086), received between Jun 3, 2021 and Jun 20, 2025 — classified as 2 malfunctions.

The most frequently reported specific device problem is “Low Test Results” (2 reports).

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.

Reports received per month

Nov 2023: 0 reportsDec 2023: 0 reportsJan 2024: 0 reportsFeb 2024: 0 reportsMar 2024: 0 reportsApr 2024: 0 reportsMay 2024: 0 reportsJun 2024: 0 reportsJul 2024: 0 reportsAug 2024: 0 reportsSep 2024: 0 reportsOct 2024: 0 reportsNov 2024: 0 reportsDec 2024: 0 reportsJan 2025: 0 reportsFeb 2025: 0 reportsMar 2025: 0 reportsApr 2025: 0 reportsMay 2025: 0 reportsJun 2025: 1 reportsJul 2025: 0 reportsAug 2025: 0 reportsSep 2025: 0 reportsOct 2025: 0 reportsNov 2025: 0 reportsDec 2025: 0 reportsJan 2026: 0 reportsFeb 2026: 0 reportsMar 2026: 0 reportsApr 2026: 0 reportsMay 2026: 0 reportsJun 2026: 0 reportsJul 2026: 0 reportsAug 2026: 0 reportsSep 2026: 0 reportsOct 2026: 0 reports2024202520261
Last 36 months. The most recent month may be incomplete.

Most reported problems

Device problems

  • Low Test Results2

Patient problems

  • No Clinical Signs, Symptoms or Conditions2

Recent adverse event reports

The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.

  • MalfunctionJun 20, 2025Low Test Results; Low Test Results

    THE CUSTOMER OBSERVED A BIAS IN ATELLICA IM CA 125II PATIENT RESULTS BETWEEN REAGENT LOT 223 AND 221. THIS WAS IDENTIFIED WHEN THE CUSTOMER WAS PERFORMING LOT TO LOT COMPARISONS AS PART OF THEIR LAB PROCESS WHEN CHANGING REAGENT LOTS (FROM LOT 221 TO LOT 223). THE CUSTOMER STATES THAT QUALITY CONTROL (QC) WAS IN RANGE AND NO PATIENTS GENERATED WITH LOT 221 WERE QUESTIONED BY PHYSICIANS; THERE IS NO INDICATION THAT ERRONEOUS RESULTS CA125II PATIENT RESULTS WERE REPORTED. THERE ARE NO ALLEGATIONS OF PATIENT HARM, CHANGES IN TREATMENT, OR DELAYS OF DIAGNOSIS IN ASSOCIATION WITH THIS EVENT.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 22302080 ↗
  • MalfunctionJun 3, 2021Low Test Results; Low Test Results

    A DISCORDANT LOW ATELLICA IM CA 125II (CA 125II) RESULT WAS OBTAINED ON A PATIENT SAMPLE. THE CUSTOMER WHEN PERFORMING A ROUTINE QUALITY CONTROL (QC) CHECK OBSERVED AN OUT OF RANGE LOW QC RESULT THAT REQUIRED AN ASSAY RECALIBRATION TO RESOLVE. THE CUSTOMER PERFORMED REPEATED TESTING ON THE ONLY PATIENT SAMPLE THAT WAS RUN PRIOR TO THE ROUTINE QC CHECK. THE PATIENT SAMPLE WHEN REPEATED RESULTED HIGHER. THE HIGHER CA 125II WAS REPORTED AS THE CORRECTED RESULT TO THE PHYSICIAN(S). THERE ARE NO REPORTS THAT TREATMENT WAS ALTERED OR PRESCRIBED OR ADVERSE HEALTH CONSEQUENCES DUE TO THE DISCORDANT, LOW ATELLICA IM CA 125II RESULT.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 11930989 ↗

Other TEST, EPITHELIAL OVARIAN TUMOR-ASSOCIATED ANTIGEN (CA125) devices

All TEST, EPITHELIAL OVARIAN TUMOR-ASSOCIATED ANTIGEN (CA125) devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page